Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 165 points (1.1%) at 15,235 as of Monday, June 17, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,604 issues advancing vs. 474 declining with 57 unchanged. The Drugs industry currently sits up 0.2% versus the S&P 500, which is up 1.0%. Top gainers within the industry include Sanofi ( SNY), up 2.4%, and Novartis ( NVS), up 0.6%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 3.86. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.32 (0.61) to $52.81 on average volume Thus far, 1.2 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $52.77-$53.46 after having opened the day at $53.24 as compared to the previous trading day's close of $52.49. GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $130.1 billion and is part of the health care sector. The company has a P/E ratio of 15.9, below the S&P 500 P/E ratio of 17.7. Shares are up 20.7% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, 1 analyst rates it a sell, and 9 rate it a hold. TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.